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Peritonitis is the most common cause of dialysis failure in
children on chronic peritoneal dialysis. We performed a
prospective study of 501 peritonitis episodes in 44 pediatric
dialysis centers located in 14 countries that examined
peritonitis etiology, efficiency of opinion-based management
guidelines, and final outcomes. Culture-negative incidence
varied significantly from 11% in North America to 67% in
Mexico. Argentina and North America had the highest rate of
Gram-negative episodes. Pseudomonas-based peritonitis was
eightfold more common in the United States than in Europe,
and correlated with the frequency of exit site cleansing and
topical mupirocin administration. Significant regional
variation in antibiotic susceptibility was noted for the first
generation cephalosporins and aminoglycosides. Initial
response rates to standardized empiric antibiotic treatment
did not differ between regions; however, final outcomes were
significantly less favorable in Eastern Europe. The wide
regional variation in culture-negative peritonitis, and the
distribution and antibiotic susceptibilities of causative
bacteria needs to be taken into consideration when the
guidelines for empiric therapy of pediatric dialysis-associated
peritonitis are revised.
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Pediatric end-stage renal disease is a rare disorder, with an
annual incidence of 1–3 per million population in the
Western world. Dialysis periods are usually shorter than in
adults since renal transplantation is the preferred end-stage
renal disease treatment modality in children. Preemptive
living donorship programs and allograft allocation principles
favoring pediatric recipients are being implemented in the
United States and Europe, reducing the need for long-term
maintenance dialysis and, as a consequence, the average size
of pediatric dialysis populations. As a downside of this most
welcome development, the individual expertise with compli-
cations of dialysis treatment is decreasing. On the other hand,
new pediatric dialysis programs are rapidly growing in many
parts of the world where renal replacement therapy is still in
the process of being available to the general population. Both
the vanishing pediatric dialysis expertise in some and the
rapidly growing need for knowledge in other regions of the
globe create a strong need for defining and implementing
standards of pediatric dialysis care, and for the systematic,
prospective collection of data regarding treatment complica-
tions and outcomes.
Chronic peritoneal dialysis (CPD) is the dialysis modality
of first choice in the majority of children and adolescents.
Although the incidence of CPD-related infectious complica-
tions has decreased in children as well as in adults within the
past two decades, bacterial peritonitis remains the most
important cause of morbidity and irreversible technique
failure in the pediatric population. In order to improve the
knowledge regarding this complication, the International
Pediatric Peritonitis Registry (IPPR) was formed by a global
consortium of 44 pediatric dialysis centers comprised of 20
European, 9 Turkish, 2 Asian, and 13 American centers.1 The
registry has collected detailed prospective information of
CPD-related peritonitis in children in order to assess the
validity of the International Society for Peritoneal Dialysis
(ISPD) pediatric peritonitis treatment guidelines2 for the
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pediatric CPD population in different parts of the world.
In the analysis presented here, we investigated the global
variation of the clinical manifestations, the spectrum
and antibiotic sensitivity patterns of causative organisms,
and the outcomes of bacterial peritonitis in children
undergoing CPD.
RESULTS
PD practices
Tenckhoff catheters with a straight ending were standard in
Eastern Europe (80% of patients), Asia (100%), and Mexico
(63%), whereas in the United States, Western Europe, Turkey,
and Argentina, 81–96% of patients had coiled catheters
(Po0.0001). In 85% of patients entered into the registry two-
cuff catheters were used, with significantly lower usage
prevalence of this variant in the United States (68%,
Po0.0001). Swan-neck catheters were more common in
Turkey (73%), Asia (92%), and Argentina (96%) than in
Eastern and Western Europe (both 15%), and were not used
at all in Mexico (0%) (Po0.0001).
Daily exit site care was applied in 13 of 14 (93%) centers
in America and Asia, in 64% (9/14) of centers in Eastern
Europe and Turkey, but only in 1 of 13 (8%) Western
European centers (Po0.001). Large regional differences
existed also with regard to the choice of exit site cleansing
agent (Po0.0001). Soap (6 of 11 sites) or sodium
hypochlorite (3 of 11) was used in North America. Povidone
iodine was used in 7 of 9 Turkish, 6 of 18 European, both
Asian but none of the US centers. Seven of 18 European sites
used b-octenidine. Topical antibiotic prophylaxis against
Staphylococcus aureus was practiced by 34/41 centers (83%).
Selective nasal decontamination was widely used in Europe,
Turkey, and Asia (25/30 centers), but in only 3 of 11 US
centers. Conversely, topical prophylaxis was administered to
the exit site more commonly in the United States (63%) and
Turkey (55%) than in the other regions (3/21¼ 14%)
(Po0.05). At the time of peritonitis, 43% of patients in the
United States, 17% in Turkey, 14% in Western Europe, 6% in
Eastern Europe, 4% in Argentina, and none in Mexico and
Asia received S. aureus prophylaxis. With respect to
microbiology practices, gram stains of dialysis effluent were
performed routinely in patients with suspected peritonitis in
11/12 centers in the United States and Asia, but were not
typically performed in one-third (10/27) of laboratories in
Europe, Turkey, and Argentina. In 55% of centers, the
effluent was cultured in bottles (BacT/Alert, BACTEC),
in 30% on blood agar plates, and in 15% other media
were used. Susceptibility testing was performed by disc
diffusion in 64% of laboratories, by broth microdilution in
21% and by using other tests in 15%, without significant
regional clustering.
Peritonitis episodes
Between October 2001 and December 2004, a total of 548
peritonitis episodes were recorded in 392 pediatric patients,
that is, 1.470.8 episodes per patient. An average of 12.7711
episodes was documented per center (European 13.5712,
American 1279.9, Asian 6.577.8; NS). Five hundred and
one episodes (91.4%) met the diagnostic and therapeutic
criteria defined by the guidelines and were included in the
analyses. The 47 episodes (8.6%) in which treatment was not
performed according to one of the regimens recommended in
the guidelines were distributed randomly among the
participating centers and regions.
Clinical presentation
The distribution of patient age and clinical symptoms at
peritonitis onset differed significantly between regions
(Table 1). The fraction of patients who were younger than
2 years was significantly greater in the United States and
Western Europe than in Turkey and Latin America. Reported
disease severity at first presentation was highest in Argentina
and mildest in Mexico. Multivariate analysis of variance
demonstrated the regional differences of disease severity score
at presentation to be independent of patient age, the
spectrum of causative organisms, and regional differences
in preferred PD modality, catheter, and tunnel configuration.
Distribution of organisms
The distribution of causative organisms is given in Table 2
and Figure 1. Culture negative peritonitis was rarest in North
America (11%) and Argentina (15%), but accounted for 42%
of all episodes in Turkey and 67% in Mexico (overall rate
29%; heterogeneity among countries Po0.0001). North
America (46%, Po0.05) and Argentina (70%, Po0.005)
had higher rates of Gram-negative episodes than the other
regions. Peritonitis episodes caused by Pseudomonas spp.
were more likely to occur in the United States (OR 2.95,
confidence interval 1.32–6.60, Po0.01) and episodes with
other Gram-negative organisms were more frequent
in Argentina (OR 2.90, confidence interval 1.24–6.79,
Po0.005) than in the other regions. Conversely, Gram-
positive infections were predominant in Europe. Patients in
Eastern Europe were significantly more likely to develop
peritonitis caused by coagulase-negative staphylococci ((OR
2.57, confidence interval 1.30–5.06, Po0.01). S aureus
peritonitis was twice as common in Western Europe than
in the United States (Po0.05). Enterococci as a cause of
peritonitis tended to occur more frequently in Turkey than in
other regions (P¼ 0.06).
Notably, peritonitis caused by Pseudomonas spp. was
significantly more common in patients from centers where
exit site care was performed more than twice per week
(Po0.005), where mupirocin cream was administered to the
exit site (Po0.005) and where non-sterile cleansing agents
(saline, soap) were used (Po0.001).
Empiric antibiotic therapy
Assignment to high-risk (glycopeptide) vs low-risk
(cefazolin) therapy varied significantly (Po0.0001) between
regions, from 100% cefazolin (Asia) to 93% glycopeptide
usage (Argentina). The rate of adherence to the empiric
Kidney International (2007) 72, 1374–1379 1375
F Schaefer et al.: PD-associated pediatric peritonitis o r i g i n a l a r t i c l e
treatment schedule recommended by the guidelines ranged
from 43% (Asia) to 89% (Argentina) (Po0.0001).
Significant regional variability of Gram-positive sensitivity
to the first generation cephalosporin cefazolin was observed,
with sensitivity rates significantly below average in the United
States and above average in Eastern Europe (Table 3). In
contrast, glycopeptide sensitivity was 96–100% without
regional differences. Approximately 80% of Gram-negative
and 50% of Gram-positive organisms were sensitive to the
third generation cephalosporin ceftazidime, without differ-
ences between the regions. Aminoglycoside sensitivity was
88% on average for Gram-negative and 77% for Gram-
positive organisms. Aminoglycoside sensitivity was signifi-
cantly below average in Eastern Europe (Po0.05). Eighteen
percent of Gram-negative organisms in Eastern Europe were
resistant to aminoglycosides as compared to only 8% being
resistant to ceftazidime.
Peritonitis outcomes
Ninety-four percent of patients showed clinical improve-
ment, and 55% were completely asymptomatic with clear
dialysis effluent to be within 3 days of empairic antibiotic
therapy (Table 4). The rate of patients with a good clinical
response appeared to be lower in patients from Argentina;
however, this difference was largely accounted by the greater
initial disease severity and the high incidence of Gram-
negative infections in patients from this country. After 4
weeks, all patients from Argentina showed full functional
recovery.
Conversely, full resolution of clinical symptoms was
associated with Mexican origin and, independently, a low
disease severity score and the absence of S. aureus,
Pseudomonas spp. and other Gram-negative infections (all
Po0.005).
Significant sequelae affecting PD function were observed
more commonly in Eastern Europe, where CPD was
permanently discontinued in 20% of patients following the
peritonitis episodes as compared with 8% in the total
population (Po0.0001). Moreover, catheter exchange was
required more frequently (12/46, i.e. 26% of all episodes)
in patients from Eastern Europe than in the other regions
(44/445, i.e. 10%, P¼ 0.005). Poor outcome was indepen-
dently associated with the Eastern European region and a
straight tunnel configuration (both Po0.005), whereas the
choice of empiric treatment, patient age, and the other risk
factors assumed in the guidelines were not predictive. Among
the PD practices preferentially applied in Eastern Europe, the
use of Tenckhoff catheters with a straight ending was
associated with an increased rate of post-peritonitis techni-
que failure (13 vs 7%, P¼ 0.05).
Table 1 | Patient age and clinical symptoms at time of diagnosis in 491 episodes of non-fungal peritonitis
All USA Mexico Argentina
Western
Europe Eastern Europe Turkey Asia P-value
Age o2 years 69 (13%) 17 (19%) 3 (11%) 0 (0%) 32 (18%) 7 (14%) 8 (5%) 2 (15%) 0.001
Marked effluent cloudiness 348 (70%) 44 (60%) 13 (48%) 19 (76%) 95 (62%) 40 (85%) 124 (77%) 13 (100%) o0.0001
Temperature 4381C 231 (47%) 27 (40%) 7 (26%) 16 (64%) 83 (55%) 34 (72%) 57 (35%) 7 (54%) o0.0001
Severe pain 209 (42%) 30 (42%) 4 (15%) 18 (72%) 69 (45%) 24 (51%) 61 (38%) 3 (23%) o0.0001
Disease severity score 2.0271.15 1.9871.12 1.4170.93* 2.7271.02# 2.1971.11 2.4171.15 1.8271.11 1.4671.66* o0.0001
Po0.05 in last column indicates significant heterogeneity between regions; individual regions differing significantly from average percentage are marked in bold.
*Po0.05 vs Argentina, Western and Eastern Europe. #Po0.05 vs USA, Turkey, Mexico, Asia.
Table 2 | Distribution of causative organisms by region
All USA Mexico Argentina Western Europe Eastern Europe Turkey Asia P-value
N 378 74 9 23 125 42 96 9
Fungal 10 (3%) 3 (4%) 0 (0%) 0 (0%) 4 (3%) 1 (2%) 2 (2%) 0 (0%) NS
Coag-neg. staph. 85 (22%) 11 (15%) 1 (11%) 1 (4%) 32 (26%) 16 (38%) 23 (24%) 1 (11%) o0.01
S. aureus 78 (21%) 10 (14%) 4 (44%) 5 (22%) 34 (27%) 6 (14%) 19 (20%) 0 (0%) o0.05
Streptococci 31 (8%) 7 (9%) 1 (11%) 0 (0%) 13 (10%) 3 (7%) 5 (5%) 2 (22%) NS
Enterococci 20 (5%) 1 (1%) 0 (0%) 0 (0%) 8 (6%) 2 (5%) 9 (9%) 0 (0%) 0.05
Other Gram-pos. 21 (6%) 8 (11%) 0 (0%) 1 (4%) 4 (3%) 2 (5%) 5 (5%) 1 (11%) NS
Pseudomonas 28 (7%) 12 (16%) 0 (0%) 3 (13%) 2 (2%) 1 (2%) 7 (7%) 3 (33%) o0.0005
Other Gram-neg. 105 (28%) 22 (30%) 3 (33%) 13 (57%) 28 (22%) 11 (26%) 26 (27%) 2 (22%) NS
Po0.05 in last column indicates significant heterogeneity between regions; individual regions differing significantly from average percentage are marked in bold.
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Figure 1 | Distribution of culture results according to regions.
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DISCUSSION
In this paper, we present the results of a unique global
collaboration of pediatric nephrologists dedicated to improve
peritoneal dialysis care in children. The analysis of 501
pediatric peritonitis episodes treated in 44 pediatric dialysis
units on three continents demonstrates significant regional
variability of the clinical presentation, bacterial spectrum,
and treatment outcomes, providing a strong rationale for
allowing site-specific adaptations in general clinical practice
guidelines.
The most striking regional variation was observed with
regards to the rate of culture-negative peritonitis episodes.
In Mexico, Turkey, and the Asian centers, effluent cultures
remained sterile in 36–67% of cases, in contrast to 11–23% in
the other regions. A survey of the laboratory procedures
applied in the individual centers did not reveal any systematic
differences in culture techniques that would explain these
marked differences. Hence, we assume that other issues such
as incubation of insufficient effluent volumes, long transport
times in rural areas, and extreme ambient temperatures may
adversely affect culture results in these regions. Most previous
peritonitis studies in adults and children, typically performed
in experienced centers in well-developed countries, reported
culture-negative rates of less than 20%,3–5 a number which
has subsequently been used as an acceptable maximum in PD
quality assurance programs. Our study demonstrates that on
a global scale, many PD units are far from meeting these
standards. International peritonitis treatment guidelines
should give special consideration to the management of
culture-negative peritonitis.
Another important finding of this global survey is the
large regional variation of the distribution of causative
organisms. In comparison with a pediatric peritonitis
survey performed in the 1990s in Mid Europe,6 we noted
an overall shift from Gram-positive to Gram-negative
causative organisms. In the view of the generally decreasing
incidence of CPD-related peritonitis, we believe that the
apparent increase in Gram-negative infections largely reflects
Table 3 | Regional distribution of in vitro antibiotic sensitivities
All regions USA Argentina Western Europe Eastern Europe Turkey P-value
Cefazolin
(All) 105 (55%) 10 (30%) 4 (36%) 37 (60%) 20 (80%) 33 (55%) o0.005
(Gram-pos.) 88 (70%) 7 (50%) 4 (100%) 35 (70%) 15 (94%) 26 (63%) 0.05
(Gram-neg.) 16 (25%) 3 (16%) 0 (0%) 2 (17%) 4 (57%) 7 (39%) 0.06
Ceftazidime
(All) 113 (69%) 18 (82%) 9 (75%) 32 (67%) 18 (72%) 33 (65%) NS
(Gram-pos.) 31 (52%) 2 (67%) 1 (100%) 12 (50%) 6 (55%) 10 (50%) NS
(Gram-neg.) 81 (80%) 16 (84%) 8 (73%) 20 (83%) 11 (92%) 23 (77%) NS
Aminoglycosides
(All) 222 (81%) 38 (79%) 14 (88%) 83 (89%) 25 (69%) 55 (82%) 0.09
(Gram-pos.) 116 (77%) 12 (67%) 2 (100%) 56 (86%) 15 (63%) 29 (81%) 0.09
(Gram-neg.) 105 (88%) 26 (87%) 12 (86%) 27 (96%) 9 (82%) 26 (87%) NS
Glycopeptides
(Gram-pos.) 182 (97%) 23 (100%) 6 (100%) 72 (96%) 24 (96%) 48 (98%) NS
Ciprofloxacin
(All) 169 (93%) 19 (90%) 15 (94%) 80 (94%) 18 (86%) 29 (94%) NS
Mexico and Asia excluded due to insufficient numbers of available resistograms. Numbers indicate absolute numbers and percentage of organisms tested sensitive.
Po0.05 in last column indicates significant heterogeneity between regions; individual regions differing significantly from the average percentage are marked in bold.
Table 4 | Response to empiric therapy and final outcomes of peritonitis by regions
All USA Argentina Mexico
Western
Europe
Eastern
Europe Turkey Asia P-value
N 491 72 18 26 149 46 159 13
3-day disease severity score 0.3370.69 0.370.5 1.071.2 0.070.2 0.470.7 0.270.5 0.370.6 0.671.3 o0.0001
3-day clinical response 460 (94%) 69 (96%) 18 (72%) 26 (96%) 141 (95%) 46 (100%) 148 (93%) 12 (92%) o0.0001
3-day complete symptom
resolution
271 (55%) 34 (47%) 8 (32%) 25 (93%) 86 (58%) 26 (57%) 87 (55%) 5 (38%) o0.0001
4-wk full functional recovery 429 (89%) 63 (89%) 25 (100%) 23 (88%) 133 (90%) 34 (76%) 139 (90%) 12 (92%) o0.005
Relapsing peritonitis 52 (10%) 6 (8%) 2 (8%) 2 (7%) 13 (9%) 8 (17%) 21 (13%) 0 (0%) NS
Temporary PD discontinuation 12 (2.5%) 4 (6%) 2 (8%) 1 (4%) 2 (1%) 2 (4%) 1 (1%) 0 (0%) NS
Permanent PD discontinuation
(technique failure)
39 (8%) 7 (10%) 0 (0%)) 2 (8%) 8 (5%) 9 (20%) 12 (8%)) 1 (8%) 0.05
Fungal peritonitis was excluded.
Po0.05 in last column indicate overall heterogeneity among regions; individual regions differing significantly from overall mean/percentage are marked in bold.
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a decreased absolute frequency of Gram-positive peritonitis.
The latter may be explained by minimized touch con-
tamination due to improved handling and connection
technologies, and by the implementation of S. aureus
prophylaxis programs.7 However, the proportion of
Gram-negative organisms varied widely between regions,
accounting for 70% of culture-positive infections in Argen-
tina and 46% in the United States, but only around 25% in
the European countries. As Gram-negative peritonitis is
typically associated with a severe clinical course, it is not
surprising that patients in Argentina presented with the most
severe clinical symptoms at onset of disease of all patients in
the registry.
The reasons for this marked geographical variation of
the bacterial spectrum are most likely multifactorial.
Environmental influences such as climate and humidity
may play a role, as well as the age distribution of the
patients. Gram-negative infections were more frequently
observed in young infants (data not shown), the propor-
tion of whom was highest in the United States. Moreover,
we noted important regional differences in various aspects
of PD practices, including catheter and tunnel configuration,
exit site care, and the routine use of topical antibiotic
prophylaxis. Some of these factors have been reported
to affect the incidence of PD-related infections,8,9 and
they may also impact on the distribution of peritonitis
causative organisms observed in different parts of the world.
For instance, the incidence of S. aureus peritonitis was low in
the United States (14%), where most sites followed
mupirocin prophylaxis protocols and 43% of the patients
(as compared with 0–17% in other regions) received
mupirocin at the time when the peritonitis episode occurred.
Conversely, the incidence of pseudomonas peritonitis was
eightfold higher in the United States than for instance in
Western Europe. This mupirocin-resistant microorganism
may preferentially colonize exit sites frequently humidified
by daily washing (standard in the United States but not
in Western Europe) and the administration of mupirocin
cream (practiced in two-thirds of the United States but none
of the Western European sites). The observed significant
association of pseudomonas peritonitis frequency with
frequent exit-site care, use of non-disinfectant cleansing
agents and topical mupirocin administration is in keeping
with this interpretation.
A further challenge to future empiric antibiotic treatment
guidelines is the local variation of antibiotic sensitivities.
Whereas Gram-negative ceftazidime resistance averaged
around 20% without regional differences, the sensitivity of
Gram-positive organisms to first generation cephalosporins
varied significantly from 50% in the United States to 94% in
the Eastern European countries. Conversely, aminoglycoside
resistance was slightly more common in Eastern Europe than
in other regions. This variability most likely reflects antibiotic
treatment preferences in different regions, which are in turn
influenced by local experience and treatment guidelines, cost
considerations and, at least for some drugs, availability issues
and marketing activities. Future peritonitis treatment guide-
lines should allow for local resistance patterns. For instance,
although the empiric use of an aminoglycoside instead of
ceftazidime would have increased Gram-negative coverage by
13% in Argentina and Western Europe, the advantage was
only 3% in the United States and in Eastern Europe, 10%
more Gram-negative organisms were sensitive to ceftazidime
than to aminoglycosides. Hence, regular assessments of local
sensitivity patterns and ‘informed’ selection of empiric
therapy should be a cornerstone of future peritonitis
treatment algorithms.
Treatment outcomes showed some geographical variation.
Although the early course appeared favorable in Mexico and
adverse in Argentina, these differences were largely explained
by marked differences in the initial disease severity and the
distribution of causative organisms.
The late functional sequelae of peritonitis, assessed here
for the first time in pediatric patients, were more evenly
distributed, with significantly less favorable results in the
Eastern European population where catheter exchange was
required most frequently and PD ultimately failed after a
single peritonitis episode in as many as 20% of patients. Our
analysis suggests that the preferential use of straight rather
than coiled catheters in Eastern Europe may play a role. In
patients with post-peritonitic adhesions, such catheters may
provide inferior drainage compared with pig-tail catheters.
Notably, neither the choice of empiric antibiotic therapy nor
the ‘correct’ assignment of antibiotic therapy according to the
risk profile suggested in the pediatric peritonitis treatment
guidelines contributed to the regional outcomes. Hence,
certain PD practices may have a greater impact on PD
outcomes than the particular choice of empiric antibiotic
therapy.
Our findings have important consequences for PD
practices. Although the relevance of individual asso-
ciations from observational registries should ideally be
tested in prospective clinical trials, this is frequently
not feasible in small populations and may not even
be justified when apparently superior practices do not
involve greater cost or potential risks to the patients.
In turn and based on our findings, we propose to abandon
the use of straight-end catheters, because they were
associated with poor functional recovery. Local monitoring
of resistance patterns should guide the choice of
empiric antibiotic treatment of peritonitis, and should
replace the treatment assignment by putative risk factors
recommended in the previous pediatric guidelines. The
observed increased risk of pseudomonas peritonitis asso-
ciated with topical mupirocin also raises doubts about the
current concept of topical prophylaxis. In addition, our study
indicates the potential roles of the frequency of exit-site care
and the choice of cleansing agents as peritonitis risk factors.
Hence, in the field of infection prophylaxis, the results of
the IPPR should stimulate comparative prospective trials to
objectively define the risk-benefit ratios of individual
strategies.
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MATERIALS AND METHODS
Data collection
The IPPR exclusively utilized online data entry via an Internet-based
web platform (www.peritonitis.org).1 Data pertaining to basic
patient and PD modality characteristics, clinical presentation with
peritonitis, microbiological results, empiric treatment and its
subsequent modifications, clinical treatment response, and final
outcomes were submitted prospectively along the course of a
peritonitis episode and automatically checked for accuracy and
consistency. In addition, center-specific demographic data and PD
practices were collected by means of an online questionnaire.
Data protection was ensured as the data input was anonymized.
The registry protocol was approved by the ethical committee/
institutional review board at each participating center.
Monitoring in the IPPR was restricted to those patients who
developed peritonitis episodes. Patients remaining peritonitis-free
were not registered, nor was the total duration of dialysis times in
those who developed peritonitis. Hence, information pertaining to
the number of peritonitis episodes per time at risk is not available.
Definitions
In accordance with the ISPD guidelines, the diagnosis of peritonitis
required (i) cloudy effluent, (ii) an effluent cell count of at least
100 cells/ml, and (iii) at least 50% polymorphonuclear cells in the
differential cell count. The catheter exit site appearance was
characterized according to a standardized scoring system (ESS).3
Treatment of peritonitis was assumed to be in accordance with
the ISPD guidelines if the diagnostic criteria for peritonitis were
fulfilled and/or an organism was grown on culture and empiric
antibiotic treatment was initiated according to the recommended
risk stratification schemes.2 The guidelines suggested the use of
ceftazidime combined with a first generation cephalosporin
(cefazolin or cefalothin) in children with an assumed low risk,
and combined with a glycopeptide (vancomycin or teicoplanin) in
patients assumed to be at a high risk for a severe course of infection.
An increased risk was assumed in children with severe clinical
symptoms, younger than 2 years of age, recent or current exit-site
infection and a history of an Methicillin-resistant S. aureus (MRSA)
infection. The empiric use of one of these antibiotic combinations, but
not treatment selection according to the suggested risk stratification,
was a prerequisite for inclusion of patients in the registry.
A standardized Disease Severity Score (range 0–5) was calculated
as the sum of 3 score points for pain and 2 for fever.3 Empiric
treatment response was considered satisfactory if the Disease
Severity Score 72 h after the start of empiric antibiotic therapy
was p2 and effluent cloudiness had visually improved. Final
treatment outcome was judged according to the occurrence of a
relapse, temporary or permanent PD discontinuation, and the
attainment of full functional recovery. The latter was assumed if PD
was continued without functional impairment (such as ultrafiltra-
tion loss or intraabdominal adhesions compromising fluid flow),
irrespective of whether a relapse occurred or a catheter exchange was
performed.
Relapsing peritonitis was defined by recurrence of peritonitis
with the same organism (defined by biochemical differentiation and
resistogram, or the occurrence of two episodes remaining culture-
negative) within 4 weeks after termination of antibiotic treatment.
Antibiotic resistograms accompanied most, but not all positive
cultures. Some resistograms included a priori assumptions (Gram-
negative organisms regarded as resistant to glycopeptides; entero-
cocci regarded as resistant to cephalosporins).
Statistical analyses
For statistical analysis, the following regions were defined: Western
Europe (nine sites in Germany, two in Italy, one each in France,
Austria, Finland, Greece, UK), Eastern Europe (three sites in Poland,
one in Czech Republic), Turkey (three sites in Ankara, two in
Istanbul, two in Izmir, one each in Antalya, Bursa), North America
(11 sites in the United States), Mexico (Mexico City) Argentina
(Buenos Aires), and Asia (Seoul (Korea), Bangkok (Thailand)).
Student’s w2 tests were used to assess differences between
proportions, and analysis of variance followed by Newman–Keuls
tests for multiple comparisons to assess differences between group
means. The association of outcomes with potential effector variables
was assessed using univariate and multivariate logistic regression
models.
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